NASDAQ
Dyne Therapeutics, Inc. (DYN)
♥ 566 Thanks from members
Dyne Therapeutics, Inc. (DYN) exhibits a polarized market profile, propelled by a major FDA Priority Review acceptance for z-rostudirsen in exon 51 DMD and a $375 million public offering that introduces near-term dilution pressure alongside launch funding.